Atopic Dermatitis | AbbVie | M19-850
Pharmaceutical Company/Sponsor:
AbbVie
Code:
M19-850
Title:
A Phase 3b, Open-Label Treatment Extension Study of Upadacitinib For the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis Who Completed Treatment in Study M16-046
Type:
Interventional
Phase:
3
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Upadacitinib
Status:
Recruiting
Link for Additional Information:
